孟鲁司特对过敏性紫癜患儿尿白三烯的影响

目的测定尿LTE4变化，探讨孟鲁司特治疗过敏性紫癜（HSP）的疗效。方法60例患儿随机分为两组各30例，急性期均予常规治疗，治疗组同时孟鲁司特口服，恢复期继续孟鲁司特治疗2周；对照组恢复期泼尼松治疗2周。ELISA法检测两组治疗前、后尿LTE4水平。结果维持治疗1周，治疗组比对照组LTE4下降更明显（t=28．860，P〈0．05），但仍高于正常（F=46．268，P〈0．05），需继续治疗。维持治疗2周，两组患儿尿LTE4接近正常（F=2．796，P〉0．05），且治疗组比对照组下降更明显（t=4．777，P〈0．05）。两组肾脏损害无统计学意义（χ^2=-0．218，P〉0．05）。结论LTE4参与了HSP发病过程，孟鲁司特治疗HSP可提高疗效、改善预后，副作用小。

The effects of Montelukast on urinary leukotriene of henoch-schonleinpurpura in children

Objective By measuring the change of urinary LTE4 to discussed Montelukast treatment HSP effect.Methods Sixty patients were randomly divided into a control group of 30 patients treated with conventional therapy,in the recovery use of prednisone treatment in 2 weeks.The treatment group of acute period and recovery period continued to oral Montelukast for 2 weeks.Used ELISA for the detection of the two groups before and after treatment urinary LTE4 levels.Results On one week after treatment,the treatment group levels of LTE4 decreased more obviously(t = 28.860,P < 0.05),But still higher than the normal(F = 46.268,P <0.05),and after two weeks,the treatment group and control group of LTE4 near normal(F = 2.796,P > 0.05),compared to the control group decreased obviously(t = 4.777,P <0.05).Two groups of kidney damage without difference(χ2=0.218,P > 0.05).Conclusion Leukotriene involved in the pathogenesis of HSP,Montelukast for the treatment of HSP can improve the curative effect,to improve the prognosis,small side effect.